Brian Wiley
Executive Director
-
Demonstrated success as a Senior Executive in the start-up and small company environment with an excellent ability to understand and drive the key aspects of building an organization. 30 years of bio-pharmaceutical experience, including 25 years in oncology, with exceptional relationships in industry and with KOLs for solid tumors and hematologic malignancies.
-
Accomplished business development track record including multiple large M&A, clinical collaboration, and licensing deals. Additional experience in negotiating and managing manufacturing, institutional and government licenses and agreements.
-
Extensive commercialization achievements include numerous oncology product launches and leadership roles in all aspects of strategic planning and execution. Direct experience in leading launch planning, market access, medical affairs, sales, distribution, manufacturing and building commercial infrastructure.
Brian has over 30 years of experience in the biopharmaceutical industry, with over 25 years dedicated to oncology. His experience as a senior executive includes numerous licensing transactions, collaborations, M&A, as well as public and private financings. His commercialization experience includes multiple product launches in oncology. Brian has been a major contributor to licensing and M&A deals exceeding $5 billion.
​
Brian is the Principal and Founder of Boston BioConsulting, LLC, a consulting firm that specializes in corporate strategy, business development, and pre-commercial planning for the biopharmaceutical industry. Brian’s current roles include serving as Chief Business Officer, Strategic Advisor and Senior Executive for multiple emerging biopharma companies. Prior to Boston BioConsulting, Brian served as Chief Commercial Officer and Head of Business Development at NewLink Genetics. Brian also served in various leadership and management roles at Celgene, Gloucester Pharmaceuticals, Millennium and Aventis. Brian has a marketing degree from the Pennsylvania State University.